Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/7/2026, 12:00:00 AM
Pfizer presented mid-stage Phase 2b clinical trial data for its monthly injectable weight-loss drug, berobenatide, at the American Diabetes Association (ADA) meeting on June 7, 2026. Medium importance estimated as positive data in the competitive obesity market is a significant milestone for Pfizer's pipeline.
Korean Translation
2026년 6월 7일, 화이자가 미국 당뇨병 학회(ADA)에서 월 1회 주사 제형 비만 치료제 베로베나타이드(berobenatide)의 임상 2b상 데이터를 발표함. 비만 치료제 시장의 성장성을 고려하여 중간 중요도로 예상됨.
Related Recent Events
Synopsys Inc (SNPS) · Other
An investor day to discuss long-term financial targets and strategy is scheduled.
9/30/2026, 12:00:00 AM
Broadcom Inc (AVGO) · Earnings Release
Broadcom's Q3 2026 earnings release on September 3, 2026. This event is expected to have a medium impact as it will provide critical updates on AI revenue growth, scheduled
9/3/2026, 12:00:00 AM
NetApp Inc (NTAP) · Earnings Release
Next quarterly earnings for Q1 fiscal year 2027 are scheduled.
8/26/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Next quarterly earnings for Q3 2026 are scheduled to be reported on 2026-08-24, with analysts forecasting an EPS of $1.46; low importance is estimated as market impact is typically limited for scheduled announcements, scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart is scheduled to release its Q2 FY2027 earnings results on 2026-08-20, scheduled. Medium importance is estimated as earnings releases typically trigger significant market volatility.
8/20/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Other
Microsoft declared a quarterly dividend of $0.91 per share with an ex-dividend date of August 20, 2026, scheduled.
8/20/2026, 12:00:00 AM